BR112022007837A2 - Combinação de um inibidor de ahr e um anticorpo inibidor de pd1 e seu uso no tratamento de câncer - Google Patents

Combinação de um inibidor de ahr e um anticorpo inibidor de pd1 e seu uso no tratamento de câncer

Info

Publication number
BR112022007837A2
BR112022007837A2 BR112022007837A BR112022007837A BR112022007837A2 BR 112022007837 A2 BR112022007837 A2 BR 112022007837A2 BR 112022007837 A BR112022007837 A BR 112022007837A BR 112022007837 A BR112022007837 A BR 112022007837A BR 112022007837 A2 BR112022007837 A2 BR 112022007837A2
Authority
BR
Brazil
Prior art keywords
component
inhibitor
treatment
ahr
cancer
Prior art date
Application number
BR112022007837A
Other languages
English (en)
Inventor
GUTCHER Ilona
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR112022007837A2 publication Critical patent/BR112022007837A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

COMBINAÇÃO DE UM INIBIDOR DE AhR E UM ANTICORPO INIBIDOR DE PD1 E SEU USO NO TRATAMENTO DE CÂNCER. A presente invenção refere-se a combinações de pelo menos dois componentes, componente A e componente B, o componente A sendo um inibidor de AhR e o componente B sendo pembrolizumab ou nivolumab. Um outro aspecto da presente invenção refere-se a combinações de três componentes, componente A, componente B e componente C; o componente A sendo um inibidor de AhR, o componente B sendo pembrolizumab ou nivolumab e o componente C sendo um agente farmacêutico adicional. A presente invenção refere-se ainda ao uso de tais combinações como descrito no presente documento para a preparação de um medicamento para o tratamento ou profilaxia de uma doença, particularmente para o tratamento ou profilaxia de cânceres de mama, trato respiratório, cérebro, órgãos reprodutivos, trato digestivo, trato urinário, olho, fígado, pele, rim, cabeça e pescoço, tireoide, paratireoide e metástases distantes dos mesmos, linfomas, sarcomas e leucemias.
BR112022007837A 2019-12-16 2020-12-14 Combinação de um inibidor de ahr e um anticorpo inibidor de pd1 e seu uso no tratamento de câncer BR112022007837A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962948430P 2019-12-16 2019-12-16
EP19216672 2019-12-16
PCT/EP2020/085938 WO2021122434A1 (en) 2019-12-16 2020-12-14 Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112022007837A2 true BR112022007837A2 (pt) 2022-07-05

Family

ID=73790120

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007837A BR112022007837A2 (pt) 2019-12-16 2020-12-14 Combinação de um inibidor de ahr e um anticorpo inibidor de pd1 e seu uso no tratamento de câncer

Country Status (11)

Country Link
US (1) US20230084899A1 (pt)
EP (1) EP4076462A1 (pt)
JP (1) JP2023505907A (pt)
KR (1) KR20220128622A (pt)
CN (1) CN114786674A (pt)
AU (1) AU2020403801A1 (pt)
BR (1) BR112022007837A2 (pt)
CA (1) CA3164474A1 (pt)
IL (1) IL293861A (pt)
MX (1) MX2022007438A (pt)
WO (1) WO2021122434A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
CN105461687B (zh) * 2014-08-26 2020-06-19 北京京奉医药科技有限公司 含二氢哒嗪酮的喹啉类化合物及其用途
MX2018014443A (es) * 2016-05-25 2019-04-15 Bayer Pharma AG 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas.
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
WO2019101643A1 (en) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
US11459312B2 (en) * 2017-11-21 2022-10-04 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides

Also Published As

Publication number Publication date
IL293861A (en) 2022-08-01
JP2023505907A (ja) 2023-02-13
EP4076462A1 (en) 2022-10-26
CA3164474A1 (en) 2021-06-24
MX2022007438A (es) 2022-07-19
US20230084899A1 (en) 2023-03-16
CN114786674A (zh) 2022-07-22
KR20220128622A (ko) 2022-09-21
WO2021122434A1 (en) 2021-06-24
AU2020403801A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
HRP20200180T1 (hr) Derivati (aza-)izokinolinona
CL2023000847A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
DOP2022000135A (es) Compuestos moduladores de la diacilglicerol quinasa
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
BR112017020948A2 (pt) composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
BR112019016300A2 (pt) ANTICORPO ANTI-FXI OU ANTI-FXIa ISOLADO, SEU USO E MÉTODO DE PREPARAÇÃO, COMPOSIÇÃO FARMACÊUTICA E ANTICORPO OU UM FRAGMENTO FUNCIONAL DO MESMO OU UMA PORÇÃO IMUNOLOGICAMENTE ATIVA DO MESMO
MX369474B (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
BR112018076639A2 (pt) quimioterapias de combinação
WO2016130800A3 (en) Pharmaceutical compositions comprising perillyl alcohol derivatives
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.
MX2020007442A (es) Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion.
AR119259A1 (es) Anticuerpos anti-cd33 y métodos de uso de los mismos
BR112018000383A2 (pt) métodos para tratar hcv
BR112022007837A2 (pt) Combinação de um inibidor de ahr e um anticorpo inibidor de pd1 e seu uso no tratamento de câncer
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
Liu et al. Polysaccharopeptide enhanced the anti-cancer effect of gamma-tocotrienol through activation of AMPK
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
BR112018015448A2 (pt) conjugado anticorpo-fármaco, composição farmacêutica, métodos para liberar um agente ativo, para tratar uma doença, para inibir progressão de tumor e para inibir, diminuir ou eliminar a capacidade metastática de um tumor, e, kit.
MX2020009355A (es) Un farmaco para tratar trastornos de una funcion de ogano o tejido y enfermedades acompa?adas por esos trastornos, y el metodo para obtenerlo.
MX2021005671A (es) Uso de disulfiram y otros compuestos para tratar cánceres con pérdida del cromosoma 16q y/o baja expresión de proteínas de metalotioneína.
BR112019001808A2 (pt) composição farmacêutica anticâncer
EA202092270A1 (ru) Применение конъюгатов антитело-лекарственное средство, содержащих агенты, разрушающие тубулин, для лечения солидной опухоли